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Abstract 
Background: In Mexico, combined chloroquine (CQ) and primaquine (PQ) treatment has been used since the late 
1950s to treat Plasmodium vivax infections. Although malaria transmission has declined, current treatment strategies 
must be evaluated to advance towards malaria elimination.
Methods: The clinical and parasitological outcome of treating symptomatic P. vivax with the 14‑day (T14) treatment 
or intermittent single dose (ISD) regimen was evaluated in southern Mexico between February 2008 and September 
2010. Patients over 12 months old with P. vivax mono‑infection and asexual parasitaemia ≥500 parasites/µl were 
treated under supervision. After diagnosis (day 0), treatment began immediately. T14 patients received CQ for 3 days 
(10, 10 and 5 mg/kg) and PQ daily for 14 days (0.25 mg/kg), while ISD patients received a single dose of CQ (10 mg/
kg) and PQ (0.75 mg/kg) on days 0, 30, 60, 180, 210, and 240. Follow‑up was done by observing clinical and labora‑
tory (by microscopy, serology and PCR) outcome, considering two endpoints: primary blood infection clearance and 
clinical response at ~28 days, and the incidence of recurrent blood infection during 12 months. Parasite genotypes of 
primary/recurrent blood infections were analysed.
Results: During the first 28 days, no differences in parasite clearance or clinical outcome were observed between 
T14 (86 patients) and ISD (67 patients). On day 3, 95 % of patients in both groups showed no blood parasites, and no 
recurrences were detected on days 7–28. Contrarily, the therapeutic effectiveness (absence of recurrent parasitaemia) 
was distinct for T14 versus ISD at 12 months: 83.7 versus 50 %, respectively (p = 0.000). Symptomatic and asympto‑
matic infections were recorded on days 31–352. Some parasite recurrences were detected by PCR and/or serological 
testing.
Conclusions: T14 was effective for opportune elimination of the primary blood infection and preventing relapse epi‑
sodes. The first single dose of CQ‑PQ eliminated primary blood infection as efficiently as the initial three‑dose scheme 
of T14, but the ISD regimen should be abandoned. A single combined dose administered to symptomatic patients in 
remote areas while awaiting parasitological diagnosis may contribute to halting P. vivax transmission. Alternatives for 
meeting the challenge of T14 supervision are discussed.
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Background
According to malaria records, which have existed in Mex-
ico since 1949, the last epidemic occurred in the 1980s. 
At that time, more than 120,000 cases were reported each 
year and malaria transmission was present in over 50 % of 
the country. Due to the intensification of control activi-
ties, transmission has now been reduced to a few residual 
foci. In fact, local transmission of Plasmodium falcipa-
rum was completely eliminated in 2000, the same year in 
which 7259 Plasmodium vivax cases were reported. The 
number of cases of the latter Plasmodium species was 
reduced to 2702 in 2009. The country is currently consid-
ered to be in the pre-elimination phase [1–4].
In most affected areas around the world, a combina-
tion treatment of chloroquine (CQ) and primaquine 
(PQ) was introduced in the 1950s to treat P. vivax blood 
and liver infections [5, 6]. In regions where parasites are 
susceptible to these drugs, the recommended doses are 
the following: CQ at 25  mg/kg bw (body weight) dur-
ing three consecutive days (10, 10 and 5 mg/kg bw) and 
PQ at 0.25–0.75 mg/kg bw during 14 days [7, 8]. In fact, 
this 14-day (T14) treatment effectively cures primary 
blood infections and is the most effective for preventing 
relapses [9]. However, in areas where CQ is no longer 
effective, it is recommended that artemisinin combina-
tion therapy (ACT) be used instead, also in combina-
tion with PQ for radical cure [8]. No studies exist on CQ 
resistance in Mexico.
Like most of the Americas, Mexico has been using the 
combination of CQ and PQ as the standard treatment for 
P. vivax malaria to date. However, PQ treatment is fre-
quently not completed due to its undesirable side effects. 
Although haemolysis due to glucose 6-phosphate dehy-
drogenase deficiency (G6PDd) in PQ-treated patients is 
a concern in malaria-affected regions [8], the Mexican 
Malaria Control Programme (MCP) has administered 
0.75 mg PQ in a single dose for decades without G6PDd 
testing [10]. In this country, G6PDd occurs in less than 
1 % of the general population (the African-related variant 
is the most common) [11–13].
In locations of difficult access, the intervals between 
blood sampling, parasitological diagnosis and patient 
treatment used to be as long as 3–4  weeks. Hence, to 
reduce the risk of transmission, febrile patients were 
blood sampled and immediately treated with a single 
dose of 10 mg of CQ and 0.75 mg of PQ per kg bw [14, 
15]. Then, after microscopy confirmation, the full T14 
treatment was administered. In 1999, an intermittent 
single dose regimen (ISD) replaced T14. The ISD regi-
men, allegedly easy to dispense under field conditions, 
comprises monthly administration of a single dose for 
3  months, followed by 3  months without dosing. This 
schedule is repeated twice each year to complete 3 years 
of treatment, with a total of 18 doses [10, 16, 17].
The first single combined CQ-PQ dose is expected to 
eliminate blood parasites, since PQ may destroy para-
sites surviving from the effect of CQ [15, 18, 19]. The 
repeated administration of ISD was intended to sup-
press cases of recurrent parasitaemia [10, 17]. How-
ever, symptomatic recurrent infections in southern 
Mexico (probably relapses) have been detected within 
12  months of the initial treatment [20]. Assessment 
and monitoring of the effectiveness of T14 and ISD 
treatment is necessary in order to assess their efficacy 
and contribution to malaria reduction, with the aim of 
advancing towards malaria elimination in the region 
[21]. The aim of the present study was to compare the 
effectiveness of the standard T14 treatment with that 
of the ISD regimen in patients living in endemic com-
munities of southern Mexico. Two endpoints were con-
sidered: their efficacy in clearing primary clinical and 
parasitological infections within 28 days post-diagnosis, 
and in treating recurrent P. vivax infections during a 
12-month period.
Methods
The protocol of this study was approved by the Ethics in 
Research Review Committee of the National Institute of 
Public Health (Mexico). Informed consent was obtained 
from all patients or the guardians of minors.
Study design
An open-labelled, non-randomized, clinical trial was 
conducted with a group of malaria patients receiving a 
combined dose of CQ and PQ with either an ISD sched-
ule or the standard 14-day treatment (T14). In both 
cases, the first dose was given on day 0, the day of diag-
nosis. The treatment dosing was adjusted according to 
the age group of a patient, as recommended by the Mexi-
can MCP for ISD and T14 [10]. The study was designed 
to evaluate two clinical and parasitological endpoints: the 
primary parasite blood infection clearance and clinical 
response at ~28 days post-diagnosis, and the incidence of 
recurrent blood infections during 12 months.
Trial registration: NIH‑USA, ClinicalTrial.gov Identifier: NCT02394197
Keywords: Plasmodium vivax, Chloroquine, Primaquine, Effectiveness, Single dose, ISD, T14, Microscopy, PCR, 
Serology, Relapse, Genotype, Southern Mexico
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Study site
The study was carried out in the Tapachula municipal-
ity and surrounding communities in southern Chiapas, 
Mexico, a region on the Guatemala border with an alti-
tude ranging from ~50–1200 meters above sea level. This 
is a hypo-endemic region showing variable malaria inci-
dence, with an annual parasite incidence (API) of 0.579–
1.523 cases/1000 inhabitants when considering only the 
affected villages for the period 2003–2007 (data from the 
Local Sanitary Jurisdiction VII). Patient recruitment was 
carried out in the diagnosis facility at the Regional Centre 
for Public Health Research-INSP (CRISP) in Tapachula 
City, where febrile individuals seeking malaria diagnosis 
and treatment can obtain free service.
Patients
Patients were recruited from February 2008 to October 
2009 and the follow-up ended in September 2010. Inclu-
sion criteria were: (1) patients over 12 months old; (2) P. 
vivax mono-infection, confirmed by microscopy; (3) par-
asite densities of 500-50,000/μl of blood; and, (4) elevated 
axillary temperature (≥37.5 °C) or a history of a fever epi-
sode within the previous 48 h. Patients were excluded if 
they: (1) lived in communities that could not be reached 
by travelling for 1  h by motor vehicle from the CRISP 
centre; (2) presented signs of severe malnutrition or 
anaemia; (3) had taken an anti-malaria treatment or had 
had a malaria infection within the previous 12  months 
(to reduce the probability of incorporating patients with 
a relapse) [20]; (4) had another possible cause for their 
fever or suffered from some chronic disease; (5) were 
allergic to CQ; or, (6) were pregnant (by patient state-
ment and/or pregnancy test of women over 14) [7]. The 
pregnancy test consisted of a urine sample evaluated with 
Gestastrip II (Hycel, Jalisco, Mexico).
For practical purposes, patients were not randomized 
to form the two treatment groups (ISD and T14). Patients 
living in Tapachula City and the nearby area were pre-
ferred to administer the T14 treatment in order to facil-
itate daily supervision. On the day of diagnosis (day 0), 
patients were examined for axillary temperature, body 
weight, spleen swelling, and clinical symptoms such as 
fever, headache, myalgia, arthralgia, erythema, and jaun-
dice. Capillary blood, collected by finger pricking, was 
used to prepare thin and thick smears and to impregnate 
filter paper (Whatman #2) for parasitological and sero-
logical (DNA and antibody) analysis, respectively.
Patient treatment and follow‑up
For the ISD regimen, the standard single dose con-
sisted of 10 mg/kg of CQ and 0.75 mg/kg of PQ, which 
the patients were scheduled to take on days 0, 30, 60, 
180, 210, and 240. For the T14 treatment, the optimal 
dose was 25 mg/kg of CQ administered over a three-day 
period (10  mg/kg on days 0 and 1 and 5  mg/kg on day 
2) and PQ at 0.25 mg/kg/day given during 14 days [7, 8]. 
However, both treatment regimens were adjusted to the 
age group of patients, according to the operational table 
prescribed by the Mexican official guidelines (Additional 
file  1) [10]. For small children, tablets were crushed, 
mixed with water and spoon fed. Treated patients were 
observed during 30 min after ingesting the drugs. Those 
who vomited the first dose were re-treated with a simi-
lar dose, and those who vomited again were treated, but 
excluded from the study.
The CQ and PQ tablets were provided by the local 
malaria control programme (drug batches used during 
the study are shown in Additional file 2). The first dose 
was administered immediately after diagnosis at CRISP 
(day 0), and all subsequent doses were administered 
under supervision by a member of the study team. If a 
patient was not available to receive one or two supervised 
doses, these were left with a family member. If the next 
day the patient claimed to have taken the dose and was 
willing to continue with the medication and follow-up, 
he/she remained in the study within the semi-supervised 
group.
In case of feeling ill (having fever or presenting one of 
two other malaria symptoms) at any time during the fol-
low-up period, patients were encouraged to visit the facil-
ity at CRISP or to contact the field team by mobile phone 
(most patients or their parents had a mobile phone). 
The same recommendation was given in the event that 
patients had any question about the study. Whether 
during the treatment or follow-up period, participants 
unable to reach the facility were visited at their homes 
for treatment, clinical revision and blood sampling. All 
treated patients were scheduled for examination on days 
2, 3, 7, 14, 21, and 28 [22]. Afterwards, parasitological 
and clinical examinations were implemented monthly 
until completing the 12-month protocol. When required, 
scheduling changes were made to complete the follow-
up for each patient, as suggested by Ruebush et al. [23]. 
If patients, after the first ISD administration, were not 
at home on day 3, they were visited on day 4. Likewise, 
visits were made on day 7 ±  1, and on day 14 ±  2. For 
all patients (under ISD or T14), a visit was carried out on 
day 21 ± 2, and so on for the rest of the follow-up.
Two thick and thin blood films and a sample of blood 
impregnated in filter paper (Whatman #2) were pre-
pared at every scheduled or extra visit. Patients with 
axillary temperatures  ≥37.5  °C were symptomatically 
treated with paracetamol (acetaminophen) (10 mg/kg). A 
rapid diagnostic test (RDT) OptiMAL© [24] was applied 
to symptomatic patients when visited at home. Thick 
smears of symptomatic patients with negative RDT were 
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analysed the same day and if a recurrent P. vivax episode 
was confirmed, they were immediately treated with T14 
[8].
Parasitological diagnosis
Thick and thin blood smears were stained with 10  % 
Giemsa (pH 7.2) for 5  min. The two thick smears were 
independently examined under a light microscope by 
two trained laboratory technicians by using oil immer-
sion 100×. Asexual and sexual parasite densities were 
determined by counting the number of parasites found 
per 200 white blood cells (WBC) assuming 7000 WBC/
μl of blood [24, 25]. In case of very light infections (less 
than 10 parasites/200 WBC), 500 WBC were inspected to 
confirm the counts. At least 500 fields were examined to 
record a sample as negative. One thick smear was ana-
lysed at CRISP and the second one by another micros-
copist at the Institute of Diagnosis and Epidemiological 
Reference, the national reference laboratory of quality 
control for malaria diagnosis in Mexico. Discrepancies 
on smears results (absence versus presence of parasites 
or counts differing by 50 %) were resolved by cross vali-
dation, examined by a third experienced microscopist. 
Asexual parasitaemia was quantified using the following 
formula: parasites/µl of blood = (number of parasites per 
200/500 fields × 7000 WBC per 1 µl of blood)/number of 
WBC per 200/500 fields.
Molecular diagnosis (PCR)
Molecular diagnosis has proven to be very sensitive in 
different regions affected by malaria [26, 27]. All blood 
samples (whether taken on days 2, 3, 7, 14, ~21, or ~28, 
or thereafter during the monthly examinations) with an 
increase in the anti-P. vivax IgG antibody titre (ELISA 
OD value), were subjected to molecular diagnosis due to 
suspicion of recent malaria infection. Six 5-mm punches 
of filter paper impregnated with dried blood were used to 
extract DNA, using the QIAamp® DNA Blood Mini Kit 
(QIAGEN, Hilden, Germany) and following the manufac-
turer’s instructions. The DNA obtained was suspended in 
50 µl of water and stored at −20 °C until used. The pres-
ence of the P. vivax 18S small sub-unit ribosomal RNA 
gene was assessed as previously reported [28]. Infected 
(with P. vivax: 500, 2000 and 10,000 p/µl) and uninfected 
blood samples were included as controls.
Detection of IgG antibodies against the Plasmodium vivax 
blood stage (by ELISA)
Antibodies against the P. vivax blood stage can last for 
months or years in exposed patients. However, antibody 
titres fade out more rapidly in treated patients [29–31]. 
To reveal P. vivax re-exposure, with and without clinical 
symptoms and/or low parasitaemia in recurrent blood 
infections, retrospective research was conducted at the 
end of the 12-month follow-up period to look for native 
P. vivax blood-stage proteins in preserved blood samples 
by using ELISA, as previously reported [32]. Briefly, the 
blood samples that had been taken from each patient and 
smeared on filter paper were eluted in PBS and tested 
at 1:500 dilutions in an indirect ELISA. The reaction 
was revealed using goat anti-human IgG (H  +  L)-HRP 
(Pierce, Rockford, IL, USA) diluted 1:5000 and ABTS 
(2,2′-Azinobis [3-ethylbenzothiazoline-6-sulfonic acid]-
diammonium salt) as substrate for 60 min, and then OD 
values were recorded in a spectrophotometer (Biotek® 
model EL312) at 405 nm. Cut-off values were previously 
determined using unexposed individuals as the mean and 
2SD as 0.25 OD values (95 % confidence). The ELISA-OD 
values were plotted according to time point per patient.
Primary and recurrent Plasmodium vivax genotype 
determination
To determine the frequency of parasite genotypes, all P. 
vivax infected blood was analysed for cspr and msp3α 
by polymerase chain reaction and restriction fragment 
length polymorphism (PCR–RFLP) [20]. The homoge-
neity of P. vivax genotypes among groups was examined 
by Fisher’s exact test (α = 0.05). In addition to cspr and 
msp3α, parasite genotypes were analysed using msp3β 
after Alu I digestion to compare parasites producing pri-
mary and secondary episodes in each patient [33].
Data analysis
For each patient that completed the supervised treat-
ments and the follow-up (for 28  days and 12  months 
post-diagnosis), parasitological and clinical data were 
analysed using STATA v12. To discard the possibility that 
a sub-dose caused delay in parasite clearance, the body 
weight recorded on day 0 was used to determine the 
accuracy of doses of CQ and PQ given to patients using 
age group dosing.
The first endpoint, parasitological and clinical cure 
of the primary blood infection, was evaluated by deter-
mining the early clinical and parasitological outcome at 
2–3 days post-diagnosis, and the possible clinical and/or 
parasitological asexual parasite persistence or reappear-
ance within seven to 28 days post-diagnosis. Therapeutic 
failure (TF) was defined as the presence of parasitaemia, 
while an adequate clinical and parasitological response 
(ACPR) was considered with the absence of parasites on 
days 7–28: for these analyses, both microscopic and PCR 
results were included.
Fisher’s exact test was used to compare two or more 
independent proportions between treatment groups, 
considering gender, PCR positivity, parasite persistence, 
the presence of symptoms, and the distribution of the P. 
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vivax genotype on day 2 or 3. The Wilcoxon rank sum 
test was used for non-parametric comparisons: age, asex-
ual and sexual parasitaemia, drug doses, number of days 
of symptoms, and axial temperature. All tests of signifi-
cance were two-tailed and P values < 0.05 were consid-
ered statistically significant.
The second endpoint evaluated was by determining 
whether or not recurrent blood infections existed during 
the follow-up ending 12  months after day 0. The effec-
tiveness was calculated as the per cent of the accumu-
lated number of patients without P. vivax blood infection 
(first recurrent case) detected at each month of sampling, 
divided by the total number of patients followed up. The 
Z-test was used to determine differences in the propor-
tion of patients or samples with a recurrent infection. To 
plot the cumulative incidence of patients with the first 
recurrence, the Kaplan–Meier failure estimate was used.
Results
Demographics, clinical and parasitological characteristics 
of patients
During the recruitment period, the diagnostic facility at 
CRISP received 1,820 symptomatic patients, of which 
343 were diagnosed with P. vivax by microscopy. Of the 
153 self-reporting malaria-symptomatic patients that 
satisfied the inclusion criteria, 86 received the T14 treat-
ment and 67 the ISD regimen (Fig. 1). More patients were 
assigned to T14, expecting that several patients would 
not complete all supervised T14 doses. The proportion 
of gender and median age of participants, median and 
interquartile range (IQR) of the duration of symptoms (in 
days), and parasite densities were similar in both groups 
(Table  1). There was no difference in the proportion of 
patients indicating certain malaria symptoms, such as 
fever, headache, myalgia, arthralgia, chills, jaundice, blis-
ters, and erythema (Table 1).
Most patients recruited for the study were living in 
an area of 18  ×  10 sq km and they were comprised of 
mostly indigenous and Mexican mestizo populations. 
Although a higher proportion of T14 patients lived in the 
Tapachula City and its surrounding areas (zone 1), and 
a higher proportion of ISD patients lived in the foothills 
(zone 2) (Additional file 3), ISD and T14 patient groups 
had similar proportions of P. vivax cspr-msp3α genotypes 
(p = 0.248; Chi square test; Additional file 4). There was 
a significantly lower CQ dose in male patients when com-
paring the ISD group (median dose 0.88/IQR 0.16) to the 
T14 group (median dose 1.0/IQR 0.29, p = 0.01).
Clinical and parasitological clearance of the primary blood 
infection during 28 days
Out of 67 participants that received the initial dose 
of ISD, 18 (26.8  %) and 23 (34.3  %) completed the 
programmed follow-up visits and the flexible-schedule 
visits, respectively. Patients missing three continuous 
scheduled visits were excluded from the follow-up. Thir-
teen patients were not accessible for one visit during the 
first 14 days, and another four missed two follow-up vis-
its. There were nine patients who withdrew, including 
four on day 2, two on day 3, one on day 7, and two on day 
14. Six patients were not willing to be subjected to finger 
pricking, two moved to inaccessible communities, and 
another took an extra medication of CQ-PQ on day 3.
Out of 86 patients with the T14 treatment, 49 (56.9 %) 
completed the 14 supervised doses. Of these, 44 com-
pleted all follow-up visits (24 as programmed and 20 
with the flexible schedule option, needed only for days 21 
and 28). Three patients missed one visit, on day 21 or 28. 
There were two withdrawals of patients afraid of finger 
pricking on day 21.
Comparison of parasite detection by microscopy and PCR
A total of 778 samples obtained from days 2 to 28, exam-
ined by both microscopy and PCR (including three sam-
ples with only gametocytes), were used to compare the 
performance of the diagnostic methods. Of these, 90.3 % 
had concordant results (35 were positive and 703 nega-
tive for P. vivax according to both methods). There were 
32 samples (4.1 %) only PCR-positive, indicating that par-
asite density was at the sub-microscopic level. Eight sam-
ples (1.22 %) were microscopy-positive but PCR negative. 
These discordant samples had parasite densities below 
100/μl (16, 28, 28, 49, 70, 82, 88, and 197 p/μl). Three 
samples (with parasite densities below 100/μl) were posi-
tive in only one of the two thick smears.
Early clinical and parasitological responses (on days 2 
and 3)
Of the T14 group, 81 and 75 were sampled during super-
vised treatment on day 2 and 3, respectively. For the ISD 
group, 57 patients were sampled on these 2 days. There 
were no differences in the clinical outcome between the 
two treatment groups (Table 2). In seven of these patients 
(three in the T14 group and four in the ISD group), small 
blisters on the lips and/or outer edges of the mouth were 
detected. In most of these patients, temperatures above 
38 °C had been registered at recruitment/diagnosis.
No difference in parasitaemia clearance was observed 
between treatments. Few patients had asexual blood par-
asites detected by microscopy on days 2 or 3 (Table  2). 
The reduction in the number of patients with asexual 
parasitaemia on day 3 with respect to day 2 was signifi-
cant and similar for both treatments (T14 p = 0.000; SD 
p = 0.016). The number of PCR-positive samples on days 
2 and 3 was higher than that determined by microscopy. 
On day 2, 41.3 % (1.87-fold higher than microscopy) and 
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34.1 % (2.3-fold higher than microscopy) of samples were 
PCR-positive for the ISD and T14 treatments, respec-
tively. Persistent parasitaemia, detected by microscopy 
and/or PCR on days 2 and 3, was inversely correlated 
to the parasite count on day 0. That is, a higher parasite 
density (median 5068/IQR 2,067) was found on day 0 in 
patients that earlier cleared blood parasites, compared 
to the density observed (median 2891/IQR 1,357, also 
on day 0) in patients that on days 2 and 3 still harboured 
blood parasites (p = 0.0375). On the other hand, parasite 
persistence was not associated with parasite genotype, 
lower CQ doses, or patient gender or age.
Treatment failure (days 7–28)
All samples from days 7 to 21 were negative by micros-
copy and PCR, regardless of the treatment (Table  2). 
A light yellowish jaundice was observed in some ISD 
and T14 patients. In some ISD patients, this symptom 
persisted through day 14, while among T14 patients, 
the proportion with light jaundice increased with PQ 
administration (representing 40 % on day 14). No patient 
reported dark urine or any other clinical symptoms of 
haemolysis. In all patients, the jaundice disappeared by 
day 28, and no additional treatment was necessary. Ery-
thema, present in some patients of both treatment sched-
ules, disappeared after completion of the treatment. 
Light jaundice, erythema and/or blisters occurred con-
comitantly in only three patients.
Light jaundice in T14-treated patients was associated 
with the number of days with malaria symptoms before 
recruitment. The group with light jaundice had a higher 
proportion of patients with more symptomatic days pre-
vious to recruitment (median of days with symptoms, 
16.5/IQR 2), compared to patients with no jaundice 
1,820 symptomatic patients and  blood film examined:   
February 2008-August 2009 
343 (18.8%) patients positive for       
Plasmodium vivax blood infection 
153 met the inclusion criteria (WHO) and agreed to participate by 
giving informed 
86 patients were allocated to T14   
67 patients were allocated to ISD 
131 patients did not meet the inclusion criteria; 
48.1% live outside the study region; 26.7% had 
recent anti-malaria medication;  6.1% pregnant; 
5.3% with asexual parasitemia  below 500/µl;  2.3% 
with other clinical complications or chronic diseases; 
10.6% unknown. 
59 (27.8%) of  212 did not give their consent.  
1477 negative for malaria 
infection 
Fig. 1 Flow chart of Plasmodium vivax patient detection and recruitment for T14 and ISD treatment regimens, in southern Mexico. D day
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(median of days with symptoms 14/IQR 4; p = 0.0067). 
The presence of these symptoms was not associated 
with parasitaemia levels on day 0, parasite persistence 
(observed on days 2 and 3), gender, or PQ dosage.
T14 and ISD: prevention/elimination of recurrent blood 
infections (Plasmodium vivax) during 12 months
To compare the frequencies of recurrent infections for 
the T14 and ISD groups, only patients that completed at 
least 3 months of follow-up were included. Thirty-seven 
and 49 patients under supervised T14 and ISD treatment, 
respectively, met this criterion. The number of recurrent 
infections that occurred in patients recruited to T14 and 
ISD groups was truthful; the recurrences  were not asso-
ciated with a particular geographic location (Additional 
file 5). Moreover, no differences were observed between 
the 18 patients that completed the semi-supervised T14 
treatment and those whose doses were all supervised. 
All samples from these 18 patients (101 blood samples 
obtained from day 3 to 28) were negative by microscopy 
and PCR, similar to the supervised group.
The comparison between the number and timing of 
recurrent blood infections in the T14 versus ISD treatment 
group is shown in Table 3 and Fig. 2. Three patients (P3, 
P47, P57) under supervised T14 had a symptomatic recur-
rent blood infection, after asymptomatic periods of about 
7–8  months (late recurrences). All these patients were 
affected by different P. vivax genotypes, but the genotypes 
of parasites during relapses were similar to those of their 
primary infections (homologous recurrent infections) 
(Table  4). Similarly, another three patients under semi-
supervised T14 (P70, P113, P149) had late symptomatic 
Table 1 Characteristics of patients participating in the study: CQ–PQ combined treatment in 14 days (T14) and intermit-
tent single doses (ISD)
F female, M male, n number of patients, IQR interquartile range
a Chi square; α = 0.05
b Two‑sample Wilcoxon rank‑sum (Mann–Whitney) test
c Fisher exact test; α = 0.05
Parameters By regimen of anti‑malarial treatment P value
Single doses (ISD) 14‑day (T14)
Total patients 67 86
By Gender (n)
Female Male Female Male 0.274a
Age range in years
 1–5 2 3 2 3 Age by gender (male/age, 
0.58; female/age, 0.413) 6–15 13 6 6 13
 16–25 6 6 9 9
 26–40 4 6 9 12
 >40 9 12 10 13
Total 34 33 36 50
Body weight: median (IQR), range 50 (25), 9.6–108 57 (20), 14–104 0.219b
Days of symptoms: median (IQR), range 5 (4), 1–20 4 (4), 1–30 0.265b
Axial temperature (°C): median (IQR), range 37.45 (1.1), 36–40 37.5 (1), 36.5–40.1 0.183b
Asexual parasitaemia/µl: median (IQR), range 4888 (5379), 512–28,940 3830 (5443), 490–28,424 0.20b
Samples with gametocytes 100 % 100 % 0.073b
Gametocytaemia/µl: median (IQR), range 697 (959), 45–5684 999 (1305), 35‑12,102
Clinical symptoms indicated by patients as having occurred within 2 days of arrival to our diagnosis facility (% of patients 
indicating each condition)
0.265c
 Fever 98.1 100
 Headache 98.1 96.5
 Mialgias 89.5 89.5
 Arthralgias 80.6 83.7
 Paroxysm 77.6 68.6
 Jaundice 11.9 12.8
 Blisters 2.9 3.4
 Pruritus 0 0
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recurrent blood infections (detected by microscopy) that 
were genetically homologous to their primary infection. 
No difference in the proportion and timing of recurrent 
episodes between supervised versus semi-supervised T14 
patients was identified (p = 0.54; Additional file 6). A sig-
nificantly higher number of recurrent blood infections 
was detected in patients under the ISD regimen (Z value 
3.85; p = 0.000) (Table 3). Eighteen of the 49 patients in 
this group had at least one recurrent blood infection, 
detected by microscopy and/or PCR. The majority of the 
recurrent episodes were symptomatic (17 of 23), whether 
confirmed by microscopy and/or PCR (Table 5; Additional 
file 7). Upon confirmation of the first symptomatic recur-
rent infection, patients were immediately treated with T14. 
Because blood samples in asymptomatic patients were 
not processed immediately after sampling, some cases of 
recurrent parasitaemia were not opportunely detected. 
The recurrent cases in this group were distributed at simi-
lar frequencies of 23.3, 20, 30, and 27.7 % within the first, 
second, third, and fourth quarters of the year. Only 33 % 
Table 2 Clinical and parasitological outcome of Plasmodium vivax affected patients treated with combined doses of CQ–
PQ for 14 days (T14) or with an intermittent single dose (ISD) 
N number of patients
* Statistical differences were detected on days 3 (p = 0.004), 7 (p = 0.007) and 14 (p = 0.002) in both treatment groups (Fisher exact test, α = 0.05)
†  As indicated by the patients, this symptom was present between visits
a n and %, number and percent of samples with asexual parasites
b Number of asexual parasites per microlitre of blood
c Only positive samples were included
d Percent of samples positive by molecular analysis
















 Clinical outcome (% with symptoms)
  Fever 10.17† 3.70† 1.8† 0 0 0
  Headache 30.51† 16.67† 3.7† 5.3† 3.3† 0
  Mialgias 1.69† 3.39† 0 0 0 0
  Arthralgias 0 0 0 0 0 0
  Blisters 5.08 6.78 7.41 3.7 1.8 0
  Erythema/pruritus 10.17 8.47 1.85 0 0 0
  Light jaundice 11.86 13.56* 11.11* 9.2* 3.6 0
 Asexual parasitaemia by microscopy
  Positivity: n, %a 14, 23.7 3, 5.0 0 0 0 2, 3.4
 p/µlb: median (IQR)c 62 (68) 157.7 (59.1) – – – 223 (163)
















 Clinical outcome (% with symptoms)
  Fever 2.67† 3.17† 0 0 0 0
  Headache 25.33† 7.94† 0 2.2† 0 0
  Mialgias 2.47† 4.0† 0 0 0 0
  Arthralgias 1.23 1.33 0 0 0 0
  Blisters 3.70 4.0 3.17 0 0 0
  Erythema/pruritus 7.41 9.33 6.35 4.1 0 0
  Light jaundice 23.46 32.0* 36.5* 40.8* 13.6 2.2
 Asexual parasitaemia by microscopy
  Positivity: n, %a 13, 16 4, 5.1 0 0 0 0
  p/µlb: median (IQR)c 118 (180) 42.4 (43.0) – – – –
  % PCR positived 34.1 8.75 0 0 0 0
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(13 of 29) of recurrent blood infections coincided with the 
administration of the scheduled ISD dose.   
For 16 of the 20 samples from ISD patients in which 
the P. vivax genotype could be obtained, the primary 
blood infections matched their respective recurrent para-
sites (Table  5; Additional file  7). No association existed 
between the genotype and the time interval between 
primary and recurrent infections. That is, five patients 
having a primary infection with genotype cspvk210-
msp3α C/msp3β V relapsed after quite different time 
intervals (days 32, 66, 95, 178, 287, and 352), and three 
patients with genotype cspvk210-msp3α B/msp3 β III also 
relapsed (with homologous parasites) after distinct inter-
vals (days 74/183, 98 and 236). With all recurrent infec-
tions treated with supervised T14, the patients had no 
further detectable recurrent infections, with one excep-
tion (patient P44, 65 days after this treatment).
Serology
 IgG antibodies against the P. vivax blood stage were 
detected by ELISA in 151 of 153 samples, with OD val-
ues from 0.3 to  >3.0 (mean 1.14 ±  0.73) on day 7 after 
the initial treatment. Antibody OD values decreased 
post-treatment, causing nearly 50 % of the patients to be 
ELISA-negative within 3 months. The antibody response 
in two patients of the ISD group remained positive, with 
low OD values, until the end of the study. However, there 
were no clinical symptoms of a recurrent blood infection 
or parasitaemia (Fig. 3).
In the T14 group, recurrent P. vivax blood infections 
were accompanied by a drastic increase in the anti-
body OD value, which decreased after the infection was 
treated with T14 (Fig. 3a). Antibody titres increased prior 
to the onset of clinical symptoms and/or parasitaemia. 
In addition, one patient (P61) likely presented asympto-
matic recurrent infections, since an increased and per-
sistently high level of antibody titres was detected on day 
95–313. The sample on day 313 was also PCR-positive 
(Fig.  3a; Table  4). Patient P149 (semi-supervised group) 
Table 3 Monthly effectiveness of T14 and ISD treatments to eliminate Plasmodium vivax recurrent infections in patients 
of southern Mexico
Only patients that completed at least 3 months of follow up were included in this table; four patients under T14 and 18 under ISD had at least one recurrent blood 
infection; a recurrent blood infection was diagnosed by RDT and/or microscopy or PCR (only two patients; P45 and P63)
Percentage effectiveness was calculated as the number of patients with no malaria infection divided by the total of patients under follow‑up
N number of patients, SD standard deviation
a ISD was provided
b Z‑test, comparing T14 and ISD, showing the proportions of patients with recurrent infections, at 95 % confidence
A. T14; N = 37
 Day of sampling (mean/SD) 29/3 59/8 92/5 124/4 152/6 185/5 214/5 247/4 277/6 305/7 336/6 370/11
 n, samples 35 33 34 30 28 28 28 25 23 25 23 27
 n 1rst P. vivax recurrence 0 0 0 0 0 0 2 1 0 1 0 0
 Cumulative lost 0 0 0 0 0 1 3 4 4 4 5 6
 % Effectiveness 100 100 100 100 100 100 94.1 90.9 90.9 87.8 87.5 87.1
B. ISD; N = 49
 Day of sampling (mean/SD) 29/3a 62/4a 93/6 121/8 154/6 187/7a 218/7a 246/7a 278/11 306/12 336/10 367/22
 n, samples 49 48 46 42 40 39 34 28 24 24 22 20
 n, 1rst P. vivax recurrence 2 1 2 1 0 1 1 3 3 2 1 1
 Cumulative lost 0 0 0 2 2 6 9 12 12 12 12 13
 % Effectiveness 95.9 93.8 89.7 87.2 87.2 83.7 80 70.2 62.1 56.7 54 50
 P valueb 0.214 0.126 0.045 0.023 0.023 0.011 0.076 0.031 0.005 0.003 0.002 0.001
Fig. 2 Cumulative incidence of Plasmodium vivax recurrences during 
the 12‑month follow‑up in groups of patients treated under supervi‑
sion with combined CQ–PQ for 14 days (T14) and intermittent single 
doses (ISD). The CI at 95 % is shown
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had high antibody titres on days 307 and 322 (on the 
latter day parasite infection was detected by PCR), sug-
gesting a long period of asymptomatic blood infection. 
In the ISD group, antibody responses against symp-
tomatic and asymptomatic recurrent infections were 
observed (Fig.  3b; Table  5; Additional file  7), but in 
three patients with increased antibody OD values (P22, 
0.186D315  →  0.57D341; P87, 0.55D121  →  1.73D149; P115, 
0.12D115 → 0.90D158), it was not possible to demonstrate 
malaria blood infection by microscopy or PCR. No cor-
relation was documented between the low PQ dos-
age in T14 or ISD and the presence of recurrent blood 
infections (Table  6). Interestingly, subjects affected with 
genotype cspvk247-msp3α/A had a serological response 
before their recurrent parasitaemia was detected (T14 
patients P47 and P61; ISD patients P45 and P80).
Discussion
The current findings demonstrate a lower performance 
in preventing relapses exerted by the ISD regimen com-
pared to the T14 standard treatment. Nonetheless, the 
first ISD single dose (CQ 10 mg and PQ 0.75 mg/kg bw) 
effectively cleared the primary P. vivax parasitaemia, in 
a similar way as the first three doses of T14. The effec-
tiveness of a single dose in clearing primary blood infec-
tions, reported earlier in El Salvador [34], Nicaragua and 
Costa Rica [14], could support the strategy (followed by 
the Mexican MCP) of giving an initial single CQ-PQ dose 
to patients suspected of having malaria until the parasi-
tological diagnosis is completed. A rapid parasite clear-
ance after the initial dose might contribute to reducing 
transmission, and therefore lead to a continuous reduc-
tion of malaria cases in Mexico.
The efficacy of a standard 25  mg/kg bw CQ dose to 
cure P. vivax infection has been proven in many differ-
ent geographic sites, including Korea [35], Colombia [36], 
Peru [37], India [38], Pakistan [39], China [40], Thailand 
[41], Afghanistan [42], Vanuatu [43], Iran [44], Ethiopia 
[45], and Mauritania [46]. A similar clinical and parasi-
tological outcome was found in Brazil when CQ only 
was administered at 10 or 25 mg/kg bw [47]. No data on 
the in  vivo effectiveness of CQ are available in Mexico 
or any other country in the Americas apart from Brazil, 
and no P. vivax resistance to CQ has been evidenced. In 
this region, a combined regimen of CQ and PQ to treat 
malaria was introduced in the 1950s and is still effective 
today, probably because PQ can effectively eliminate par-
asites with low sensitivity to CQ [8].
Primaquine is the only licensed 8-aminoquinolone 
available to malaria control programmes for the elimi-
nation of liver-dwelling hypnozoites. If left untreated, 
hypnozoites can produce relapses upon reactivation at 
variable periods of time [8, 48, 49]. However, PQ-induc-
ing acute haemolytic anaemia (AHA) in G6PD deficient 
individuals remains an undeniable thread [50, 51]. Thus, 
PQ administration is in general not recommended before 
G6PD testing. Nevertheless, PQ-induced AHA depends 
on the severity of G6PDd, which differs among the more 
than 180 G6PD variants and in accordance with the PQ 
dose administered [52]. Low PQ doses can be safely 
administered, and under field conditions where no G6PD 
tests are available, the World Health Organization has 
Table 5 Parameters of primary and recurrent Plasmodium vivax blood infections from ISD patients
Truncated (complete information is given in Additional file 6)
M male, F female, RFLP restriction fragment length polymorphism, cspr circumsporozoite gene central repeat type, msp3α merozoite surface protein 3α/β genes
a Day of sample collection
b After diagnosed with P. vivax, T14 was administered
c Continued the ISD treatment; P44, was the only patient that had a second recurrent episode after T14 was administered; D348 was positive by microscopy
Patient Age/sex Primary blood infection Recurrent infection by microscopy Serology (ELISA 
OD value/405NM; 










P6 3/F 2364 vk247‑A D241b Yes 875 vk247‑A 0.16D211 → 2.57 D241
P7 17/F 10,766 vk210‑B/III D236b Yes 14,218 vk210‑B/III 0.04D218 → 1.49 D236
P15 62/F 675 vk210‑B/IV D312b Yes 246 vk210‑B/IV 0.29D301 → > 3.0D312
P17 36/F 480 vk210/247‑B/III D108b Yes 8485 vk247‑A/I 0.18D89 → 2.1D209
P35 20/F 2241 vK210‑C/V D336b Yes 846 vK210‑C/V 0.18D308 → 1.88D336
P37 9/M 17,598 vK210‑C/V D287b Yes 866 vK210‑C/V 0.16D287 → 1.67D308
P44 60/M 2951 vk210‑C/VI D282b Yes 844 vk210‑C/VI 0.18D244 → 0.53D282
P56 42/F 7960 vk210‑C/V D178b Yes 1570 vk210/247‑A/I 0.41D147 → 1.12D178
P62 26/M 4319 vk210/247‑C/II D216b Yes 2594 vk210‑C/II 0.15D183 → 2.48 D216
P72 12/M 8059 vk210‑B/III D98c Yes 3505 vk210‑B/III 0.963D92 → 2.03D98
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recommended a single low PQ dose (0.25 mg/kg) to elim-
inate P. falciparum gametocytes [8]. In Mexico, less than 
1 % of the general population is G6PD deficient [11–13], 
and the MCP has been administering 0.75 mg/kg bw PQ 
in a single dose in the absence of G6PD testing, without 
any serious AHA symptoms having been identified.
In this study, it is likely that most cases of light jaundice, 
detected in about 12 % of the patients recruited, were due 
to infected erythrocyte lysis, and others resulted from PQ 
administration. The condition of light jaundice occurred 
mostly in patients under T14 treatment. Indeed, as this 
treatment progressed there was a greater frequency of 
jaundice. Although no severe AHA was observed and 
light jaundice did not worsen in the participants, the 
current findings warrant further studies to determine 
G6PDd in the Mexican population affected by malaria 
infection, as well as its implications for treatment of the 
same. G6PDd screening would be facilitated by the devel-
opment of diagnostic tests applicable in field conditions 
[53].
Mild pruritus was observed in 10 % of the patients in 
both treatment groups after the administration of CQ–
PQ, a condition that disappeared within 1  week. CQ-
related pruritus has been reported in a high proportion 
of Africans, in 1.9  % of Asians [54], and in Brazil [55]. 
Higher doses of CQ can produce paresthesia, diarrhoea, 
nausea, and vomiting [56], conditions not seen in patients 
of the present study.
Although many recurrent episodes were detected by 
microscopy, the serological analysis of the IgG antibody 
response to the P. vivax blood stage as well as the PCR 
diagnosis were powerful for discovering recurrent para-
site exposure and/or infections, albeit retrospectively. 
The serological test was very sensitive to antibody titres, 
which increased after re-exposure to parasites (due to 
recurrent parasitaemia), as confirmed by PCR. Accord-
ingly, the serological follow up confirmed parasite clear-
ance and the absence of new blood infection. It is possible 
that there were some recurrent infections cleared with-
out treatment, as evidenced by the antibody response. 
This situation was reported in Peru [57].
Relapse episodes represent the most important 
difficulty that impedes the elimination of P. vivax 
transmission [58]. Early relapses can appear in tropi-
cal regions as soon as 2  weeks post-primary blood 
infection [49, 59–61]. Although the blood level of CQ 
was not measured in this study, other reports have 
estimated that CQ therapeutic concentrations may 
remain for 20–35 days after treatment, thus suppress-
ing early relapse episodes [58, 62–64]. In ISD patients, 
the first recurrent blood infections were detected on 
days 31 and 32, when CQ might have been at sub-
therapeutic levels. The consideration of these epi-
sodes as relapses is supported by the fact that these 
patients had low recurrent parasitaemia and no par-
asites were detected, either by microscopy or PCR, 
seven to 21  days post-diagnosis. In T14 patients, the 
first recurrent blood infections were found on or after 
day 28 post-diagnosis. Other studies, such as those 
conducted in Pakistan [39] and Afghanistan [42], are 
also in accordance with the idea that most recurrent 
blood infections with P. vivax occur within 1  year of 
the primary infection. The low transmission rate in 
southern Mexico [65] makes re-infection by an infec-
tive mosquito bite unlikely. If in fact most recurrent 
cases found herein can be attributed to a relapse from 
hypnozoites in the liver, they should be caused by 
genetically homologous parasites [20]. Accordingly, in 
the present study most of the recurrent infections had 
the same genotype as that of the primary infection. 


































Fig. 3 IgG antibodies against the Plasmodium vivax blood stage 
in blood samples. a 37 patients treated with T14 and b 49 patients 
under ISD, during the 3–12 month follow‑up. Most patients had posi‑
tive ELISA OD values on day 7 after the initial treatment. Following 
treatment, OD values decreased or were negative, except in patients 
with recurrent blood infections. Squares with (+) indicate sympto‑
matic P. vivax blood infections. Square with (×) indicate asymptomatic 
P. vivax that were microscopy and/or PCR‑positive. The ELISA OD 
cut‑off value is indicated with a hidden red line
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On the other hand, there was no correlation between 
genotype and relapse latency.
The lack of effectiveness of the ISD regimen was 
evidenced by the fact that relatively few of the recur-
rent blood infections (33  %) were suppressed by the 
programmed single doses. Moreover, as these patients 
developed parasitaemia they might have been involved 
as sources of infection before the ISD was adminis-
tered. The time interval from the primary to the first 
short- and long-term recurrent infections, as well as 
the overall pattern of re-infection, partially resembles 
the outcome reported in Central America, where P. 
vivax strains produced higher numbers of long-term 
relapse episodes. Worldwide, the T14 treatment has 
proven to be the most effective treatment for elimi-
nating P. vivax relapses [9]. Since the PQ treatment 
was introduced in Mexico in 1959, the difficulty of 
completing a 14-day treatment has represented the 
main hurdle for malaria control. The attempts to 
reduce this scheme to a 5-day treatment resulted in 
a higher incidence of relapse [66]. Similar to India 
[48] and Colombia [67], in Mexico relapse episodes 
have occurred after short- and long-term periods of 
latency [20]. In the current contribution, T14 could 
eliminate almost 100  % of relapses occurring within 
6 months and 87 % of those appearing in 12 months. 
T14 was less effective in Colombia, eliminating 87.4 % 
of relapses occurring within 4  months [68] and 85  % 
within 6  months [69] after treatment. In the present 
study, each patient with a long-term recurrent epi-
sode received the appropriate dose of PQ for his or 
her body weight. Therefore, relapses in these patients 
appear to be due to problems in drug absorption or 
low PQ metabolism, as observed in other regions [70, 
71].
Although the efficacy of ISD for eliminating primary 
infections is herein documented, relapses occurred 
unpredictably at any time within 12  months after the 
first dose. This treatment scheme has been abandoned 
by the Mexican MCP. The present pre-elimination status 
of Mexico requires new strategies for the most thorough 
detection and treatment of cases [72]. Although the use-
fulness of the more efficacious T14 might be constrained 
by its low patient compliance, 59  % of the recruited 
patients complied with the supervised T14 treatment. 
Patients with semi-supervised regimen (with family 
supervision) showed similar outcomes. Hence, this alter-
native would increase the number of patients receiving 
effective treatment, and to achieve elimination of malaria 
in Mexico and other sites with similar epidemiological 
characteristics. In addition to flexibility in dose schedul-
ing, another factor that could improve malaria control 
programmes is the determination of the appropriate 
adjustments to PQ dosing [72], which should be the sub-
ject of future studies.
Conclusions
The first dose of CQ-PQ in the ISD regimen effectively 
cleared primary clinical and parasitological P. vivax 
blood infections, in a similar way as the initial three doses 
of the T14 scheme. A single combined dose administered 
to symptomatic patients in remote areas while awaiting 
parasitological diagnosis may contribute to halting P. 
vivax transmission. The supervised T14 treatment was 
much more effective for preventing recurrent infections. 
Moreover, the semi-supervised T14 (with family supervi-
sion) was also effective for patients that did not strictly 
comply with the supervised scheme. On the other hand, 
it is clear that at the individual level, ISD scored very 
low compared to T14 in preventing relapses and should 
Table 6 Comparison of patients with or without Plasmodium vivax recurrent blood infection and the doses of CQ and PQ 
managed
n number of patients, CQ chloroquine, PQ primaquine
a Three patients were not included, since after treatment they had an increase in antibody titres but there was no parasite detected by microscopy or PCR; 
recommended total doses: for ISD, CQ 10 mg/kg and PQ 0.75 mg/kg bw; for T14, CQ 25 mg/kg and PQ 3.5 mg/kg bw
b Wilcoxon rank‑sum (Mann–Whitney) test at 95 % CI
Treatment regimen Patients with recurrent
P. vivax infection:




ISD No 28a 9 (8.18–10) 0.625(0.56–0.72)
Yes 18 9.91 (9–15) 0.69 (0.6–1.0)
P valueb 0.069 0.107
T14 No 33 26.4(24–29.4) 3.75 (3.33–4.2)
Yes 4 27.3 (23.6–29.4) 3.82 (3.31–4.11)
P valueb 0.941 0.941
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therefore be abandoned. Further research should be con-
ducted to determine the ideal PQ dosing.
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